"We are pleased with the overall performance of our business in the first quarter, despite ongoing supply chain challenges and a constrained hospital capex spending environment. While we had a slow start in terms of AcQMap cases, we saw a progressive increase in procedure volume by quarter end," said David Roman, President & CEO of Acutus. "The recently published RECOVER AF study data demonstrate the profound impact we have on patient care, and we believe AcQMap’s proven capability to personalize ablation therapy and improve outcomes sets the business up for growth in 2023 and beyond."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on AFIB:
- Acutus Medical Announces Preliminary Unaudited First Quarter 2023 Results
- Acutus Medical Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Acutus Medical management to meet virtually with BTIG
- Acutus Medical price target lowered to $1.00 from $1.91 at Canaccord
- Acutus Medical sees FY23 revenue $18M-$21M, consensus $20.46M
